J&J talc unit faces skepticism on bankruptcy settlement support
Send a link to a friend
[April 12, 2023]
By Dietrich Knauth
(Reuters) - A Johnson & Johnson company on Tuesday defended its second
attempt to resolve talc lawsuits in bankruptcy, telling a U.S. judge it
can quickly build consensus around its $8.9 billion settlement offer
despite doubts about its assertion that 60,000 plaintiffs would support
the deal.
The proposed settlement has divided lawyers representing cancer victims,
many of whom claimed ahead of Tuesday's court hearing before U.S.
District Judge Michael Kaplan in Trenton, New Jersey that J&J had
created the illusion of widespread support for a deal that would deny
plaintiffs just compensation.
Linda Richenderfer, an attorney for the U.S. Trustee - the U.S.
Department of Justice's bankruptcy watchdog - said in court that J&J
subsidiary LTL Management had not adequately explained its assertion
that two-thirds of talc claimants would support the deal, especially
given opposition from lawyers representing plaintiffs who were active in
LTV's first bankruptcy.
"We just can't reconcile that with the numbers that were in front of us
in the first bankruptcy case," the DOJ's Linda Richenderfer said. "Where
are these claimants coming from and who are these claimants?"
Kaplan said he shared Richenderfer's concerns, but would not take any
action to stop LTL's second bankruptcy filing until he gets more
information.
J&J faces more than 38,000 lawsuits that have been consolidated in
federal court in New Jersey alleging that its talc products sometimes
contained carcinogenic asbestos, and those cases have been on hold while
LTL pursues a bankruptcy settlement. J&J has said its baby powder and
other talc products are safe, do not cause cancer or contain asbestos.
In 2021, J&J divided its consumer business in two and offloaded the talc
lawsuits onto a newly created subsidiary that almost immediately filed
for Chapter 11, a tactic that could halt the lawsuits and force
plaintiffs into a global settlement in bankruptcy court.
LTL's first bankruptcy case was dismissed as improper after the 3rd U.S.
Circuit Court of Appeals ruled that the company was not in "financial
distress."
[to top of second column]
|
Bottles of Johnson & Johnson baby powder
line a drugstore shelf in New York October 15, 2015. REUTERS/Lucas
Jackson
LTL attorney Greg Gordon said at
Tuesday's court hearing that the second bankruptcy is different
because the company has fewer assets available and more support for
a bankruptcy settlement.
Lawyers for those who say use of J&J's talc products caused cancer
on Tuesday spoke for and against the settlement, a day after a
faction of plaintiffs alleged that J&J's settlement was
"fraudulently and collusively" co-signed by plaintiffs' attorneys
with "exaggerated" numbers of clients.
Gordon called that an "over the top accusation," saying plaintiffs'
support for the settlement is real and substantial. Any doubts about
it could quickly be put to rest by allowing them to vote on the
settlement, he added.
David Molton, who represented the official committee of talc
claimants in LTL's first bankruptcy, said the second bankruptcy
filing must be dismissed so that cancer victims can have their day
in court.
"Hundreds of victims of J&J's products have died waiting for justice
to be done," Molton said.
Mikal Watts, who represents clients who support the deal, said that
the settlement offers the first real chance for women with cancer to
get a payout from J&J. The women should have a chance to vote on the
existing deal, Watts said.
Gordon said LTL is "still getting a handle on" the total number of
talc claims, but it believes it has support from two-thirds talc
claimants.
LTL's proposed settlement would address not only the cases that are
pending in federal court, but also cases that have not yet been
filed.
It expects to file a formal bankruptcy plan by May 14.
(Reporting by Dietrich Knauth, Editing by Alexia Garamfalvi and Bill
Berkrot)
[© 2023 Thomson Reuters. All rights
reserved.]This material may not be published,
broadcast, rewritten or redistributed.
Thompson Reuters is solely responsible for this content. |